Stephen B. Kay Family Professor of Medicine, Dana-Farber Cancer Institute
Internal Medicine
Dr. Robert J. Mayer, MD
|
|
Give Review
Robert Mayer is an expert in the field of Internal Medicine. He attended Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School has a rank of 1 in research and a 12 in primary care He received 2 awards: "Fellow (FASCO)" and "Super Doctor". Robert Mayer is a published doctor and has 84 publications published. The lastest was: 'Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.'
Publications
- Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
- Aspirin and COX-2 inhibitor use in patients with stage III colon Cancer.
- Anal Carcinoma: Impact of TN Category of Disease on Survival, Disease Relapse, and Colostomy Failure in US Gastrointestinal Intergroup RTOG 98-11 Phase 3 Trial.
- Association of TP53 Mutational Status and Gender with Survival After Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803.
- Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine Tumors.
- Clinical practice guidelines for Cancer care: utilization and expectations of the practicing oncologist.
- Perspective: A Culture of Respect, Part 2: Creating a Culture of Respect.
- Perspective: A Culture of Respect, Part 1: The Nature and Causes of Disrespectful Behavior by Physicians.
- Locally advanced anaplastic pancreatic adenoCarcinoma with initial response to FOLFIRINOX and rapid progression after five months.
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803.
- Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803.
- Documenting the Natural History of Patients With Resected Stage II AdenoCarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observ...
- Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer--A Study of ...
- Multivitamin use is not associated with Cancer recurrence or survival in patients with stage III colon Cancer: findings from CALGB 89803.
- Prognostic factors derived from a prospective database dictate clinical biology of Anal cancer: the intergroup trial (RTOG 98-11).
- Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic Cancer: phase III trial of the Cancer and Leukemia Group B (CA...
- By the way, doctor. I read that President Obama had a virtual colonoscopy. Is this the colon Cancer screening test that everybody should be getting instead of a regu...
- A step forward in the treatment of advanced biliary tract Cancer.
- The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future.
- Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancr...
- By the way, doctor. We have screening tests for other Cancers. How about pancreatic Cancer?
- Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon Cancer: Cancer and Leukemia ...
- A compendium of potential biomarkers of pancreatic Cancer.
- p27Kip1 in stage III colon Cancer: implications for outcome following adjuvant chemotherapy in Cancer and leukemia group B protocol 89803.
- Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric Cancer.
- US intergroup Anal carcinoma trial: tumor diameter predicts for colostomy.
- Targeted therapy for advanced coloRectal cancer--more is not always better.
- Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
- Induction therapy for poor-prognosis Anal cAnal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).
- Association of family history with Cancer recurrence and survival among patients with stage III colon Cancer.
- Systemic treatment of coloRectal cancer.
- By the way, doctor. Cancer of the small intestine.
- Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the Anal cAnal: a randomized controlled trial.
- A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of coloRectal cancer hepatic metastases: cancer...
- Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic coloRectal cancer?
- Association of dietary patterns with Cancer recurrence and survival in patients with stage III colon Cancer.
- Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon Cancer: results of CALGB 89803.
- Adjuvant treatment of coloRectal cancer.
- The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic coloRectal cancer.
- Multicenter phase II and translational study of cetuximab in metastatic coloRectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
- Systemic treatment of patients who have coloRectal cancer and inflammatory bowel disease.
- Impact of physical activity on Cancer recurrence and survival in patients with stage III colon Cancer: findings from CALGB 89803.
- Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant Rectal cancer: GI INT 0144.
- Cancer and leukemia group B gastrointestinal Cancer committee.
- Fifty years of clinical research by the leukemia committee of the Cancer and leukemia group B.
- ColoRectal Cancer Screening Clinical Practice Guidelines.
- Hepatic arterial infusion versus systemic therapy for hepatic metastases from coloRectal cancer: a randomized trial of efficacy, quality of life, and molecular markers...
- Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon Cancer: final report of Intergroup 0089.
- Colon Cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
- A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenoCarcinoma.
- Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Gr...
- Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levami...
- Systemic therapy for coloRectal cancer.
- Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and leukemia group B study.
- Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon Cancers.
- APC promoter hypermethylation contributes to the loss of APC expression in coloRectal cancers with allelic loss on 5q.
- Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine Tumors.
- Two steps forward in the treatment of coloRectal cancer.
- Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled Analysis.
- Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic coloRectal cancers.
- Phase II trial of cetuximab in patients with refractory coloRectal cancer that expresses the epidermal growth factor receptor.
- Gastrointestinal Cancer in older patients.
- Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
- Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III Rectal cancer: findings from Intergroup Trial 0114.
- Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected Rectal cancer: findings from the Intergroup 0114 Study.
- Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of coloRectal cancer.
- A phase II study of docetaxel in patients with metastatic carcinoid Tumors.
- Esophageal Cancer.
- Association of hospital procedure volume and outcomes in patients with colon Cancer at high risk for recurrence.
- Influence of body mass index on outcomes and treatment-related toxicity in patients with colon Carcinoma.
- Follow-up strategies after curative resection of coloRectal cancer.
- Characterization of sporadic colon Cancer by patterns of genomic instability.
- Accuracy of determining nodal negativity in coloRectal cancer on the basis of the number of nodes retrieved on resection.
- Impact of diabetes mellitus on outcomes in patients with colon Cancer.
- A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic coloRectal cancer.
- Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
- Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled Analysis.
- Acute diarrhea during adjuvant therapy for rectal cancer: a detailed Analysis from a randomized intergroup trial.
- A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic coloRectal cancer.
- Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon Cancer.
- A phase II trial of gemcitabine in patients with advanced hepatocellular Carcinoma.
- Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an Analysis of Intergroup 0089.
- A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic Carcinoma.
Schools
Harvard Medical School
Mt Sinai Hospital
National Cancer Institute
Sidney Farber Cancer Institute
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Commercial Insurance Company
- Connecticare
- First Health (Coventry Health Care) PPO
- Group Health Cooperative
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Fellow (FASCO)
- Super Doctor
Education
-
Mount Sinai School of Medicine -
Harvard Medical School
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Carl J. O'Hara, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marvin M. Adner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judy E. Garber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glenn Dranoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Divya Prabhu, MB BS
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shilpa Kodati, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer R. Brown, MD |
|
|
Dr. Rasmia A. Khalid, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzanne George, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edwin P. Alyea III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stavros N. Moysidis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shih-Ho Lue, MD |
|
|
Dr. Wolf W. Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katharine E. Morley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Idriss El Koussaimi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harry E. Potter, MD
This Doctor is OpenDoctor Recommended.
|